Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,605
Roche Holding AG News & Analysis
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
10 global stocks for a recession
These undervalued stocks come from high-quality companies in defensive sectors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,789.70 | 43.80 | 0.50% |
| CAC 40 | 7,950.17 | 8.53 | 0.11% |
| DAX 40 | 21,732.05 | 4.85 | 0.02% |
| Dow JONES (US) | 44,885.09 | 2.96 | 0.01% |
| FTSE 100 | 8,673.96 | 27.08 | 0.31% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,930.36 | 248.61 | 1.26% |
| Nikkei 225 | 39,572.49 | 58.52 | 0.15% |
| NZX 50 Index | 12,995.01 | 66.63 | 0.52% |
| S&P 500 | 6,111.70 | 40.53 | 0.67% |
| S&P/ASX 200 | 8,532.30 | 38.60 | 0.45% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |